EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Artelo Biosciences's enterprise value is $-3.22 Mil.
Artelo Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.90 Mil. Therefore, Artelo Biosciences's EV-to-EBITDA for today is 0.33.
The historical rank and industry rank for Artelo Biosciences's EV-to-EBITDA or its related term are showing as below:
ARTL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.99 Med: 0 Max: 1.73
Current: 0.33
During the past 10 years, the highest EV-to-EBITDA of Artelo Biosciences was 1.73. The lowest was -3.99. And the median was 0.00.
ARTL's EV-to-EBITDA is ranked better than 85.65% of 453
companies
in the Biotechnology industry
Industry Median: 9.26
vs ARTL: 0.33
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Artelo Biosciences EV-to-EBITDA Historical Data
The historical data trend for Artelo Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Artelo Biosciences's EV-to-EBITDA
For the Biotechnology subindustry, Artelo Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artelo Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Artelo Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Artelo Biosciences's EV-to-EBITDA falls into.
Artelo Biosciences's current Enterprise Value is $-3.22 Mil.
Artelo Biosciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Artelo Biosciences's PE Ratio for today is calculated as:
Artelo Biosciences's share price for today is $1.3746.
Artelo Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.160.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Artelo Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Artelo Biosciences (Artelo Biosciences) Business Description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARTL has been successfully added to your 